Skip to main content
    W

    West Pharmaceutical Services Inc (WST)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $414.27
    -3.53 (-0.84%)

    Market Cap: $29.01B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    West Pharmaceutical Services Inc (WST) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    West Pharmaceutical Services (WST) has a market cap of $29.01B and an enterprise value of $28.78B. Its return on invested capital of 16.85% compares with a 6.96% median across 11 similar companies.

    Total Valuation

    Enterprise value is 0.80% below the market cap, as cash exceeds debt.

    Market Cap$29.01B
    Enterprise Value$28.78B
    Latest price (Nov 17, 2026)$414.27

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 10, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Last Ex-Dividend DateNov 10, 2026
    Next Payment DateNov 18, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.67% in the quarter ended Jun 30, 2026 and shrank 1.52% a year over 2 years.

    Shares Outstanding70.80M
    Shares Change (YoY)-1.94%
    Shares Change (QoQ)-1.67%
    Share Count Growth (2Y CAGR)-1.52%

    Valuation Ratios

    Sales and book value multiples are 8.8x and 9.8x. Its year-end P/E ranged from 27.5x to 59.6x from 2016 to 2025.

    P/E Ratio45.0x
    Forward P/E43.3x
    P/S Ratio8.8x
    Forward P/S8.5x
    P/B Ratio9.8x
    P/TBV Ratio10.2x
    P/FCF Ratio67.1x
    P/OCF Ratio43.8x
    PEG Ratio4.1

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 33.8x EBITDA and 66.6x free cash flow.

    EV / Earnings50.9x
    EV / Sales8.6x
    EV / EBITDA33.8x
    EV / FCF66.6x

    Price Statistics

    The stock is up 58.65% over 52 weeks and trades 8.21% above its 50-day average.

    Beta (1Y)0.62
    52-Week Change+58.65%
    1-Month Change+8.04%
    3-Month Change+17.57%
    6-Month Change+36.39%
    5-Year Change-4.02%
    10-Year Change+442.71%
    Total Return (1Y)+59.01%
    Total Return (3Y CAGR)+6.72%
    Total Return (5Y CAGR)-1.41%
    Return vs SPY (1Y)+47.84%
    Max Drawdown (1Y)-18.76%
    Max Drawdown (3Y)-53.79%
    Sharpe Ratio (1Y)1.51
    Correlation with SPY (1Y)0.28
    50-Day Average$382.84
    200-Day Average$322.83
    52-Week Range$223.37 to $437.99
    RSI (14 Days)63.0
    Average Volume (20 Days)771.34K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.82x current liabilities, and total debt is 0.07x shareholder equity.

    Current Ratio2.82x
    Quick Ratio2.12x
    Debt / Equity0.07x
    Debt / EBITDA0.24x
    Debt / FCF0.46x
    Interest Coverage150.98x

    Returns and Efficiency

    Return on invested capital is 16.85% over the last 12 months, against a 5-year average of 19.14%.

    Return on Equity (ROE)18.89%
    Return on Assets (ROA)13.86%
    Return on Invested Capital (ROIC)16.85%
    ROE (5Y Average)20.93%
    ROA (5Y Average)15.35%
    ROIC (5Y Average)19.14%
    Asset Turnover0.83x
    Inventory Turnover4.67x
    Receivables Turnover4.76x
    Cash Conversion Cycle111 days

    Taxes

    Income tax took 20.79% of pretax income over the last 12 months.

    Income Tax (TTM)$144.20M
    Effective Tax Rate20.79%

    Scores

    WST has an Altman Z-Score of 19.50, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score19.50
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $3.33B over the last 12 months is up 12.38% from the 12 months before.

    Revenue$3.33B
    Revenue Growth (YoY)+12.38%
    Gross Profit$1.22B
    Operating Income$680.40M
    Pretax Income$693.60M
    Net Income$564.90M
    EBITDA$860.80M
    Reported EPS (TTM)$9.20

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 73.28% of the $4.08B in total assets.

    Cash and Equivalents$435.80M
    Total Debt$202.90M
    Net Cash$232.90M
    Net Cash Per Share$3.29
    Working Capital$1.17B
    Shareholder Equity$2.99B
    Book Value Per Share$42.23
    Tangible Book Value$2.88B
    Tangible Book Per Share$40.61
    Total Assets$4.08B
    Total Liabilities$1.09B

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $225.30M of capital spending, operating cash flow left $436.90M of free cash flow.

    Operating Cash Flow$662.20M
    Capital Expenditures$225.30M
    Free Cash Flow$436.90M
    FCF Per Share$6.21
    Depreciation and Amortization$181.40M
    Dividends Paid$62.40M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 20.45%, against a 5-year average of 22.73%.

    Gross Margin36.79%
    Operating Margin20.45%
    Pretax Margin20.85%
    Net Margin16.98%
    EBITDA Margin25.87%
    FCF Margin13.13%
    Gross Margin (5Y Average)37.92%
    Operating Margin (5Y Average)22.73%
    Net Margin (5Y Average)19.37%

    Growth

    Revenue grew 2.12% a year over 3 years, and EPS fell 5.25% a year.

    Revenue Growth (3Y CAGR)+2.12%
    Revenue Growth (5Y CAGR)+7.44%
    EPS Growth (3Y CAGR)-5.25%
    EPS Growth (5Y CAGR)+8.94%
    FCF Growth (3Y CAGR)+2.19%
    FCF Growth (5Y CAGR)+9.48%
    Operating Income Growth (3Y CAGR)-7.29%
    Book Value Per Share Growth (2Y CAGR)+6.64%
    Tangible Book Per Share Growth (2Y CAGR)+6.97%

    Revenue and profit by year

    Dividends and Yields

    WST pays out 11.53% of earnings as dividends.

    Dividend Per Share (Annual)$1.04
    Dividend Yield0.25%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+5.20%
    Dividend Growth (5Y CAGR)+5.51%
    Payout Ratio11.53%
    FCF Payout Ratio14.28%
    Earnings Yield2.22%
    FCF Yield1.49%
    Buyback Yield1.52%
    Shareholder Yield1.74%

    Full dividend history

    Stock Splits

    The last split was a 2-for-1 forward split on Sep 27, 2013.

    Last Split DateSep 27, 2013
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 12 similar companies, WST has the 2nd highest P/E and the 3rd highest P/S.

    P/E Ratio45.0x vs 17.9x median
    P/S Ratio8.8x vs 2.9x median
    ROIC16.85% vs 6.96% median
    Revenue Growth (Trailing 4 Quarters, YoY)+12.38% vs +9.01% median
    Dividend Yield0.25% vs 0.63% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 8.56% and EPS growth at 19.40% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+8.56%
    EPS Growth Forecast (2Y CAGR)+19.40%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About WST

    What is WST's market cap?

    West Pharmaceutical Services has a market cap of $29.01B. Its enterprise value, which adds debt and subtracts cash, is $28.78B.

    What is WST's P/E ratio?

    West Pharmaceutical Services has a trailing P/E ratio of 45.0x and a forward P/E of 43.3x.

    How many shares of WST are outstanding?

    West Pharmaceutical Services has 70.80M shares outstanding. The count is down 1.94% from a year earlier.

    Does WST pay a dividend?

    Yes. West Pharmaceutical Services pays $1.04 a share a year, a dividend yield of 0.25%.

    How much debt does WST have?

    West Pharmaceutical Services has $202.90M of total debt and $435.80M of cash and equivalents, a net cash position of $232.90M.